ICD-10-CM Code C90.00

Multiple myeloma not having achieved remission

Version 2021 Billable Code

Valid for Submission

C90.00 is a billable code used to specify a medical diagnosis of multiple myeloma not having achieved remission. The code is valid for the fiscal year 2021 for the submission of HIPAA-covered transactions. The ICD-10-CM code C90.00 might also be used to specify conditions or terms like abnormal gamma globulin level, al amyloidosis, amyloid light chain amyloidosis due to multiple myeloma, hypogammaglobulinemia, hypogammaglobulinemia due to multiple myeloma, iga myeloma, etc

ICD-10:C90.00
Short Description:Multiple myeloma not having achieved remission
Long Description:Multiple myeloma not having achieved remission

Tabular List of Diseases and Injuries

The Tabular List of Diseases and Injuries is a list of ICD-10 codes, organized "head to toe" into chapters and sections with guidance for inclusions, exclusions, descriptions and more. The following references are applicable to the code C90.00:

Inclusion Terms

Inclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
  • Multiple myeloma with failed remission
  • Multiple myeloma NOS

Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Abnormal gamma globulin level
  • AL amyloidosis
  • Amyloid light chain amyloidosis due to multiple myeloma
  • Hypogammaglobulinemia
  • Hypogammaglobulinemia due to multiple myeloma
  • IgA myeloma
  • IgD myeloma
  • IgG myeloma
  • Kappa light chain myeloma
  • Lambda light chain myeloma
  • Light chain disease
  • Light chain myeloma
  • Light chain nephropathy
  • Light chain nephropathy due to multiple myeloma
  • Monoclonal free kappa light chain present
  • Monoclonal free lambda light chain present
  • Monoclonal free light chain present
  • Monoclonal IgA present
  • Monoclonal IgD present
  • Monoclonal IgG present
  • Multiple myeloma
  • Myeloma kidney
  • Myeloma-associated amyloidosis
  • Myeloma-associated amyloidosis
  • Neuropathy associated with dysproteinemias
  • Neuropathy due to multiple myeloma
  • Non-secretory myeloma
  • Osteoporosis co-occurrent and due to multiple myeloma
  • Osteosclerotic myeloma
  • Paraneoplastic neuropathy
  • Paraneoplastic peripheral neuropathy
  • Renal involvement in malignant disease
  • Renal involvement in malignant disease

Diagnostic Related Groups

The ICD-10 code C90.00 is grouped in the following groups for version MS-DRG V38.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2020 through 09/30/2021.

  • 820 - LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH MCC
  • 821 - LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH CC
  • 822 - LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITHOUT CC/MCC

Convert C90.00 to ICD-9

  • 203.00 - Mult mye w/o achv rmson

Code Classification

  • Neoplasms (C00–D48)
    • Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
      • Multiple myeloma and malignant plasma cell neoplasms (C90)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021

Information for Patients


Multiple Myeloma

Also called: Plasma-cell myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones.

No one knows the exact causes of multiple myeloma, but it is more common in older people and African Americans. It can run in families. Common symptoms may include

  • Bone pain, often in the back or ribs
  • Broken bones
  • Weakness or fatigue
  • Weight loss
  • Frequent infections and fevers
  • Feeling very thirsty
  • Frequent urination

Doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. Your treatment depends on how advanced the disease is and whether you have symptoms. If you have no symptoms, you may not need treatment right away. If you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.

NIH: National Cancer Institute

  • Bence-Jones protein - quantitative (Medical Encyclopedia)
  • Bone marrow transplant (Medical Encyclopedia)
  • Multiple myeloma (Medical Encyclopedia)
  • Protein electrophoresis - serum (Medical Encyclopedia)
  • Serum globulin electrophoresis (Medical Encyclopedia)

[Learn More]

Multiple myeloma Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. The bone marrow produces red blood cells, which carry oxygen throughout the body; white blood cells, which form the body's defenses (immune system); and platelets, which are necessary for blood clotting.Multiple myeloma is characterized by abnormalities in plasma cells, a type of white blood cell. These abnormal cells multiply out of control, increasing from about one percent of cells in the bone marrow to the majority of bone marrow cells. The abnormal cells form tumors within the bone, causing bone pain and an increased risk of fractures. If the tumors interfere with nerves near the bones, numbness or weakness in the arms or legs can occur. Affected individuals may also experience a loss of bone tissue, particularly in the skull, spine, ribs, and pelvis. The deterioration of bone can result in an excess of calcium in the blood (hypercalcemia), which can lead to nausea and loss of appetite, excessive thirst, fatigue, muscle weakness, and confusion.The abnormal plasma cells in multiple myeloma produce proteins that impair the development of normal blood cells. As a result, affected individuals may have a reduced number of red blood cells (anemia), which can cause fatigue, weakness, and unusually pale skin (pallor); a low number of white blood cells (leukopenia), which can result in a weakened immune system and frequent infections such as pneumonia; and a reduced number of platelets (thrombocytopenia), which can lead to abnormal bleeding and bruising. Kidney problems can also occur in this disorder, caused by hypercalcemia or by toxic proteins produced by the abnormal plasma cells.People with multiple myeloma typically develop the disorder around age 65. Over time, affected individuals can develop life-threatening complications, but the rate at which this happens varies widely. Some affected individuals are diagnosed incidentally when tests are done for other purposes and do not experience symptoms for years.
[Learn More]